Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
40 hedge funds and large institutions have $150M invested in Dicerna Pharmaceuticals, Inc. in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 7 closing their positions.
70% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 10
2% less funds holding
Funds holding: 41 → 40 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
45% less capital invested
Capital invested by funds: $274M → $150M (-$125M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
+$3.92M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.03M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.61M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.16M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$14.4M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$2.09M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$477K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$407K |
| 5 |
Charles Schwab
San Francisco,
California
|
-$238K |
DRNA Hedge Fund Activity: Q3 2014 in Review
40 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q3 2014, worth a combined $150M — down 45% from $274M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DRNA and 6 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 17 added.
The largest buyer was Tiverton Asset Management, adding an estimated $3.92M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $14.4M.
- 40 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q3 2014, down from 41 in Q2 2014.
- Funds reported $150M of Dicerna Pharmaceuticals, Inc. stock for Q3 2014, down 45% quarter-over-quarter.
- 6 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q3 2014 and 7 closed out, a net change of -1 holder.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q3 2014 was Tiverton Asset Management, an estimated $3.92M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q3 2014 was Bain Capital Public Equity Management, an estimated $14.4M sold.
Based on aggregated 13F filings for Q3 2014.